View Older Stories View More Recent Stories

Dec 12, 2022 11:39AM Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
Nov 21, 2022 12:01PM Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
Nov 14, 2022 05:44PM Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
Sep 1, 2022 10:00AM Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.
Aug 29, 2022 04:00PM Mydecine Innovations Group Announces Common Share Subscription Agreement
Aug 19, 2022 11:06AM Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
Aug 15, 2022 09:46PM Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
Jun 17, 2022 07:00AM U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
Jun 9, 2022 07:00AM Mydecine Provides Company Update; Welcomes New Board Member
May 16, 2022 09:28PM Mydecine Announces First Quarter 2022 Financial Results and Highlights
Mar 31, 2022 10:03PM Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Mar 24, 2022 07:30AM Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Mar 3, 2022 07:30AM Mydecine To Attend March Investor Conferences
Mar 1, 2022 07:30AM Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
Feb 16, 2022 07:30AM Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
Feb 8, 2022 07:30AM Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada
Feb 3, 2022 07:30AM Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member
Feb 1, 2022 07:30AM Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
Jan 24, 2022 10:19AM Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Jan 18, 2022 07:30AM Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
Jan 13, 2022 07:30AM Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
Jan 10, 2022 07:30AM Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds
Jan 7, 2022 04:30PM Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services
Dec 22, 2021 07:30AM Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
Dec 9, 2021 10:41AM Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Dec 6, 2021 07:30AM Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Nov 16, 2021 07:30AM Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 10, 2021 07:30AM Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
Nov 3, 2021 07:30AM Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients
Oct 29, 2021 07:30AM Mydecine to Participate in Wonderland: Miami on November 8-9, 2021
Oct 27, 2021 07:30AM Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Oct 6, 2021 07:30AM Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
Oct 5, 2021 07:30AM Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
Oct 1, 2021 07:30AM Mydecine Completes Spin-Out of U.S. Cannabis Assets
Sep 24, 2021 04:40PM Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries
Sep 22, 2021 07:30AM Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Sep 2, 2021 07:30AM Mydecine to Participate in Upcoming Conferences in September 2021
Aug 24, 2021 03:30PM Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
Aug 18, 2021 07:30AM Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
Aug 16, 2021 04:55PM Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 28, 2021 07:30AM Mydecine to Participate in Upcoming Investor Events in August 2021
Jul 21, 2021 07:30AM Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds
Jul 13, 2021 07:30AM Mydecine Innovations Group Announces Launch of Mindleap Version 2.0
Jun 24, 2021 07:30AM Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Jun 23, 2021 07:30AM Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th
Jun 16, 2021 07:30AM Mydecine Unveils Artificial Intelligence Drug Discovery Program
Jun 8, 2021 07:30AM Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms
Jun 3, 2021 07:30AM Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th
May 25, 2021 07:30AM Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
May 19, 2021 07:30AM Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets
View More Recent Stories View Older Stories